Journal Watch · British Journal of Pharmacology · 2026

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium.

We conclude that the QSPainRelief model platform can reduce reliance on costly and slow trial-and-error methods in clinical drug development for chronic pain by bridging mechanistic insights and clinical needs, and representing a key enabler for more effective, faster, safer and personalised chronic pain management.

Mouraux A, Gousset S, Alvarez B et al.British Journal of Pharmacology3 min readPharma relevance 75/100

DOI: 10.1111/bph.70522PMID: 42309152Study type: clinical study

TL;DR

We conclude that the QSPainRelief model platform can reduce reliance on costly and slow trial-and-error methods in clinical drug development for chronic pain by bridging mechanistic insights and clinical needs, and representing a key enabler for more effective, faster, safer and personalised chronic pain management.

Key findings

  • Finally, we discuss remaining gaps in data, and directions of future research to strengthen the validation and predictive performance of the platform to further support its application for the development of safer and more effective combination therapies for chronic pain.
  • We conclude that the QSPainRelief model platform can reduce reliance on costly and slow trial-and-error methods in clinical drug development for chronic pain by bridging mechanistic insights and clinical needs, and representing a key enabler for more effective, faster, safer and personalised chronic pain management.

What they did

The H2020 QSPainRelief project developed a model platform for in-silico prediction of efficacy and adverse effects of analgesic drug combinations, focussing on opioid-non-opioid combination strategies. It integrates physiologically-based pharmacokinetic, pharmacodynamic and neural circuit models that capture key aspects of nociceptive processing and central nervous system (CNS) side effects, and enables more advanced personalised pain management by incorporating patient-specific variables, patient-reported outcomes and patient preferences. After discussing the problem of chronic pain treatments and critical determinants of CNS drug effects, we introduce the QSPainRelief platform development and share illustrative results on prediction of morphine-non-opioid combinations effects, and inclusion of patient preferences in dealing with the side effects using a clinical utility index model.

Full abstract (original)

Background: Opioids are prescribed widely for chronic pain despite well-recognised risks and variable long-term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects. However, identifying effective drug combinations is notoriously difficult.

What they did: The H2020 QSPainRelief project developed a model platform for in-silico prediction of efficacy and adverse effects of analgesic drug combinations, focussing on opioid-non-opioid combination strategies. It integrates physiologically-based pharmacokinetic, pharmacodynamic and neural circuit models that capture key aspects of nociceptive processing and central nervous system (CNS) side effects, and enables more advanced personalised pain management by incorporating patient-specific variables, patient-reported outcomes and patient preferences. After discussing the problem of chronic pain treatments and critical determinants of CNS drug effects, we introduce the QSPainRelief platform development and share illustrative results on prediction of morphine-non-opioid combinations effects, and inclusion of patient preferences in dealing with the side effects using a clinical utility index model.

Results & conclusions: Finally, we discuss remaining gaps in data, and directions of future research to strengthen the validation and predictive performance of the platform to further support its application for the development of safer and more effective combination therapies for chronic pain. We conclude that the QSPainRelief model platform can reduce reliance on costly and slow trial-and-error methods in clinical drug development for chronic pain by bridging mechanistic insights and clinical needs, and representing a key enabler for more effective, faster, safer and personalised chronic pain management.

Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70522 · PubMed 42309152.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this British Journal of Pharmacology study find?

We conclude that the QSPainRelief model platform can reduce reliance on costly and slow trial-and-error methods in clinical drug development for chronic pain by bridging mechanistic insights and clinical needs, and representing a key enabler for more effective, faster, safer and personalised chronic pain management.

What type of study is this?

It is a clinical study, published in British Journal of Pharmacology in 2026. The H2020 QSPainRelief project developed a model platform for in-silico prediction of efficacy and adverse effects of analgesic drug combinations, focussing on opioid-non-opioid combination strategies.

Where can I read the original paper?

The original is at the publisher via DOI 10.1111/bph.70522. PubMed ID: 42309152. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Mouraux A, Gousset S, Alvarez B et al.. In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium.. British Journal of Pharmacology (2026). DOI: 10.1111/bph.70522.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/in-silico-prediction-of-novel-effective-combinational-treatment-of-chron-h70522/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides